

## **Romanian NAMMD suspends business licence of Pharmafarm SA**

**Budapest, Hungary** – 21 June 2018 – Gedeon Richter Plc. (“Richter”) announces today that the Romanian National Agency for Medicines and Medical Devices (NAMMD) suspends with effect from 21 June 2018 the licence to operate of Pharmafarm SA (“Pharmafarm”), Richter’s wholesaler subsidiary following a breach of Good Distribution Practice.

Corrective and preventive measures to be submitted to the Authority are being currently prepared by the personnel of Pharmafarm.

The suspension of the business licence is expected to be revoked once the Authority approves the corrective and preventive measures proposed by the Company.

Pharmafarm is determined to work with NAMMD and provide a set of measures as required by the Authority.

### **About Pharmafarm**

Having been acquired by Richter in 2007, Pharmafarm through its six regional warehouses ensures an optimal territorial coverage adapted to the current needs of the local pharmaceutical market. The Company employed at the end of 2017 more than 500 people. As a member of Richter Group, Pharmafarm operates in a coordinated manner with Richter’s retail pharmacy chain.

### **About Richter**

Gedeon Richter Plc. ([www.richter.hu](http://www.richter.hu)), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalisation of EUR 4.1 billion (USD 4.9 billion) by the end of 2017, Richter’s consolidated sales were approximately EUR 1.4 billion (USD 1.6 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women’s Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women’s healthcare field worldwide. Richter is also active in biosimilar product development.

### **For more information:**

#### **Investors:**

Katalin Ördög: +36 1 431 5680

#### **Media:**

Zsuzsa Beke: +36 1 431 4888